Upcoming events – Jazz and Macrogenics look to phase III readouts
Jazz wants to expand its sleep portfolio, while Macrogenics hopes trial data will support its first new drug application.
Pharma news over the Christmas period
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Ash 2018 – Targeted AML trial expands its Beat
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Ash 2018 – Immunogen makes its case for a Jazz gig
The first day of the haematology conference sees first-in-human data from two antibody-drug conjugates belonging to Immunogen, a company eager to draw a line under a…
Go or no go? Roche, Jazz and Camarus await crucial regulatory readouts
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Ash 2018 preview – blood cancers offer biotech a chance at redemption
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Novel drug approvals set to hit a new record in 2018
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.